Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06728072 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 1 of 2 sitesv9
  2. Study sites: 1 to 2v8
  3. Eligibility criteria shortened, about 26 wordsv7
  4. Eligibility criteria expanded, about 14 wordsv6
  5. Enrollment target: 88 to 97v5
Show 3 earlier versionsHide 3 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 15, 2025 to Mar 7, 2025
    • Site details revised
    v4
  2. Site contact updatedv3
  3. Start date: Dec 15, 2024 to Mar 15, 2025
    • Primary and study completion dates: Apr 1, 2035 to Jul 1, 2035
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a 2-arm, noncomparative phase 2 trial designed to evaluate treatment outcomes with or without the addition of ciprofloxacin, metronidazole, and aspirin to first-line chemotherapy for patients with stage IV colorectal cancer (CRC).
Trial Details
NCT Number NCT06728072
Lead Sponsor Virginia Commonwealth University
Collaborators: American Cancer Society, Inc.
Conditions
(from sponsor)		 Colorectal Cancer, CRC
Related terms Colorectal Neoplasms
Enrollment 97 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov